EA201992281A1 - Связывающие молекулы, специфично связывающиеся с тау-белком - Google Patents

Связывающие молекулы, специфично связывающиеся с тау-белком

Info

Publication number
EA201992281A1
EA201992281A1 EA201992281A EA201992281A EA201992281A1 EA 201992281 A1 EA201992281 A1 EA 201992281A1 EA 201992281 A EA201992281 A EA 201992281A EA 201992281 A EA201992281 A EA 201992281A EA 201992281 A1 EA201992281 A1 EA 201992281A1
Authority
EA
Eurasian Patent Office
Prior art keywords
binding
tau protein
molecules specifically
binding molecules
specifically binding
Prior art date
Application number
EA201992281A
Other languages
English (en)
Inventor
Ярослав Юрашек
Константин Адриан Апетри
Original Assignee
Янссен Вэксинс Энд Превеншн Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Вэксинс Энд Превеншн Б.В. filed Critical Янссен Вэксинс Энд Превеншн Б.В.
Publication of EA201992281A1 publication Critical patent/EA201992281A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

Настоящее изобретение относится к связывающим молекулам и антигенсвязывающим фрагментам, которые специфично связываются с тау-белком, ассоциированным с микротрубочками. Данное изобретение также относится к диагностическим, профилактическим и терапевтическим способам, в которых применяются связывающие молекулы или антигенсвязывающие фрагменты.
EA201992281A 2017-03-28 2018-03-27 Связывающие молекулы, специфично связывающиеся с тау-белком EA201992281A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17163425 2017-03-28
PCT/EP2018/057770 WO2018178077A1 (en) 2017-03-28 2018-03-27 Binding molecules that specifically bind to tau

Publications (1)

Publication Number Publication Date
EA201992281A1 true EA201992281A1 (ru) 2020-02-13

Family

ID=58448491

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992281A EA201992281A1 (ru) 2017-03-28 2018-03-27 Связывающие молекулы, специфично связывающиеся с тау-белком

Country Status (10)

Country Link
US (1) US11028157B2 (ru)
EP (1) EP3601335A1 (ru)
JP (1) JP7109467B2 (ru)
KR (1) KR20190133191A (ru)
CN (1) CN110418804A (ru)
AU (1) AU2018241857A1 (ru)
CA (1) CA3056517A1 (ru)
EA (1) EA201992281A1 (ru)
SG (1) SG11201907927SA (ru)
WO (1) WO2018178077A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015012225A (es) 2013-03-13 2016-01-08 Prothena Biosciences Ltd Inmunoterapia tau.
SG11201808434WA (en) 2016-05-02 2018-10-30 Prothena Biosciences Ltd Antibodies recognizing tau
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
EP3583123A1 (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
MX2019013045A (es) 2017-05-02 2020-02-12 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
SG11202108414UA (en) 2019-03-03 2021-08-30 Prothena Biosciences Ltd Antibodies recognizing tau
GB201909393D0 (en) * 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100457914C (zh) 1999-04-15 2009-02-04 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
SG189174A1 (en) * 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
US8697076B2 (en) 2011-04-27 2014-04-15 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
US9518101B2 (en) 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
ZA201608812B (en) * 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
US10301379B2 (en) 2014-06-26 2019-05-28 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ES2848376T3 (es) 2014-11-19 2021-08-09 Axon Neuroscience Se Anticuerpos de tau humanizados en la enfermedad de Alzheimer

Also Published As

Publication number Publication date
JP7109467B2 (ja) 2022-07-29
WO2018178077A1 (en) 2018-10-04
US20210122810A1 (en) 2021-04-29
CA3056517A1 (en) 2018-10-04
JP2020511976A (ja) 2020-04-23
KR20190133191A (ko) 2019-12-02
CN110418804A (zh) 2019-11-05
EP3601335A1 (en) 2020-02-05
SG11201907927SA (en) 2019-10-30
US11028157B2 (en) 2021-06-08
AU2018241857A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
EA202091350A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
EA201992281A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
CY1125011T1 (el) Ενεργοποιουμενα αντισωματα enanti-cd71 και μεθοδοι χρησης αυτων
CY1124299T1 (el) Συνδυαστικες θεραπειες που περιλαμβανουν μορια αντισωματων κατα toy lag-3
CY1124118T1 (el) Αντισωματα προσδεσης θυμικης στρωματικης λεμφοποιητινης (tslp) και μεθοδοι χρησης των αντισωματων
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201792414A1 (ru) Антитела против cd166, активируемые антитела против cd166 и способы их применения
EA201892417A1 (ru) Антитела, распознающие тау
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EA201791485A1 (ru) Анти-cd47-антитела и их применения
PH12020550243A1 (en) Anti-tau antibodies and uses thereof
EA201790755A1 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201691470A1 (ru) Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека
WO2018031490A3 (en) Anti-ox40 binding proteins
EA201892412A1 (ru) Антитела, распознающие тау
CY1123781T1 (el) Anti-tnf αλφα-αντισωματα και λειτουργικα θραυσματα αυτων
AR105267A1 (es) Anticuerpos de unión a tau
AU2024202102A1 (en) Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
EA201990895A1 (ru) Антитела к о1 и варианты их применения